Linkedin Youtube
Launch Digital Edition

Webinars and Commercial Conversations — Register Now

Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.

Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace Directory

Verichem reference materials for lactate assays

December 2022—Verichem Laboratories announced the availability of a six-level, protein-based kit designed for the calibration or calibration verification of lactate assays on automated clinical systems. The liquid-stable, ready-to-use product contains concentration levels of lactate ranging from 3.2 mg/dL to 160 mg/dL. The format is free of glycols, surfactants, azides, and other interfering substances. Shelf life is 18 months from the manufacturing date.

Bio-Rad introduces Unity Next Peer QC

December 2022—Bio-Rad Laboratories has launched Unity Next Peer QC, a quality control peer comparison software that provides access to peer reporting and comprehensive quality control data.

OGT launches NGS myeloid panel, library prep workflow

December 2022—OGT launched its SureSeq Myeloid Plus panel designed to detect a range of aberrations, including single nucleotide variations, insertions/deletions, internal tandem duplications, and partial tandem duplications in 49 genes implicated in myeloid disorders such as acute myeloid leukemia, myeloproliferative neoplasms, and myelodysplastic syndrome.

Primera slide, cassette printers

December 2022—Primera Technology showcased its Signature EVO slide and cassette printers at the National Society for Histotechnology convention.

Siemens launches Innovance VWF Ac assay

November 2022—Siemens Healthineers announced that its Innovance VWF Ac assay is available to U.S. laboratories for use on the company’s BCS XP system and on Sysmex CS-2500 and CS-5100 hemostasis analyzers.

FDA clears COVID-19 PCR test on Cobas 6800/8800 systems

November 2022—Roche announced that the FDA has granted 510(k) clearance for the Cobas SARS-CoV-2 Qualitative PCR test for use on the automated Cobas 6800 and Cobas 8800 systems. It is a real-time RT-PCR test intended for the qualitative detection of nucleic acids from SARS-CoV-2 in nasal and nasopharyngeal swab specimens collected from symptomatic patients who are suspected of having COVID-19 by their health care provider. The single-well, dual-target assay includes specific detection of SARS-CoV-2 and pan-sarbecovirus detection for the sarbecovirus subgenus that includes SARS-CoV-2.

Traceable updates four products

November 2022—Traceable announced it has updated four of its products—a refrigerator/freezer digital thermometer with probe, a thermohygrometer with clock, a three-channel timer with alarm, and a four-channel timer with clock—to be more user friendly, economical, and higher performing. The updates are based on feedback that the company gathered from customer focus groups and industry conversations to learn how clinics, laboratories, academic institutions, logistics companies, and other organizations use its products.

Verichem reference materials for ethanol testing

November 2022—Verichem Laboratories announced the availability of a ready-to-use set of multilevel clinical reference materials for the calibration and calibration verification of ethanol assays on a range of diagnostic testing systems. The protein-based liquid standards are free of surfactants, glycols, azides, and other interfering substances. Each kit contains 5 mL of material per vial at the six available concentration levels and has a shelf life of 18 months when stored at 2° to 8°C. The product also contains a known linear relation for acetaminophen, lactate, and salicylate.

Thermo Fisher Scientific buys Binding Site

November 2022—Thermo Fisher Scientific announced it has entered into a definitive agreement to acquire the Binding Site Group from a shareholder group led by European private equity firm Nordic Capital. The all-cash transaction is valued at approximately $2.6 billion at current exchange rates, Thermo Fisher reported in a press release.

MARKETPLACE

TRENDING